People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Healthtech, Other Health Care, Other, Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Acutus Medical, Inc. | — | Healthtech | Series D+ | $296.3M | $68.9M | 2016 |
| Conventus Orthopaedics Inc | — | Other Health Care | Series C | $144.2M | $921.2M | 2020 |
| SpectraWAVE, Inc. | — | Other | Series C | $66.7M | $375.6M | 2019 |
| PQ Bypass, Inc. | — | Other Health Care | Series B | $56.7M | $684.5M | 2018 |
| SentreHEART Inc | — | Biotechnology | Series B | $51.0M | $992.2M | 2016 |
| Liquid Wire Inc. | — | Other Technology | Series A | $25.0M | $11.4M | 2020 |
| Breathe Technologies, Inc. | — | Biotechnology | Series A | $14.8M | $225.9M | 2017 |
| Hearme in 30 Inc | — | Other Technology | Seed | $2.7M | $3.3M | 2022 |
| Ouroboros Medical Inc | — | Biotechnology | Pre-Seed | $667K | $36.8M | 2009 |
Steven Hochberg at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steven Hochberg on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Ferrari | 2 | 15 |
| Paul Buckman | 2 | 10 |
| David Neustaedter | 2 | 7 |
| Andrew ElBardissi | 2 | 7 |
| Shaden Marzouk | 2 | 2 |
| Brian Smith | 1 | 22 |
| Beth Seidenberg | 1 | 15 |
| Casey Tansey | 1 | 14 |
| Kevin Johnson | 1 | 12 |
| PAUL LAVIOLETTE | 1 | 12 |
| Russell Hirsch | 1 | 10 |
| Chen Yu | 1 | 7 |
| J. Daniel Cole | 1 | 7 |
| Scott Huennekens | 1 | 7 |
| David Gold | 1 | 7 |
| David Bonita | 1 | 6 |
| Robert A Kukuljan | 1 | 6 |
| Victor Tong | 1 | 6 |
| D. Keith Grossman | 1 | 5 |
| David Blue | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.